Skip to main content
Caplight Logo









AccurEdit Therapeutics

AccurEdit Therapeutics

Private
JiangsuHealthcare & Life Scienceshttps://accuredit.com/

Last Round

Series A

Sep 1, 2025

Est. Valuation

$147M

Total Funding Raised

$116M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

AccurEdit Therapeutics is a biotechnology company that develops in vivo gene editing therapies and delivery technologies for the treatment of severe or life-threatening genetic and acquired diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

RNA base editingbase editingRNA editing platformgene editingRNA therapypreclinical biotechCNS therapyCRISPR alternativegenetic disease therapytransient gene therapyLNP deliverysingle nucleotide editinggRNA design

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AccurEdit Therapeutics Comparables

Compare AccurEdit Therapeutics with similar companies based on industry and business-model similarity.

AccurEdit Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shape Therapeutics
84%
AIRNA
81%
Frequency Therapeutics
79%

AccurEdit Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ASep 1, 2025
SeedSep 1, 2021

AccurEdit Therapeutics Investors

Notable investors and investment history

AccurEdit Therapeutics investors
InvestorRounds
Cormorant Asset ManagementSeed
Legend CapitalSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors increased 448% MoM, reaching 3.3K.

  • Jul 13, 2026

    Open roles increased to 71, 592% of headcount.

AccurEdit Therapeutics Filings

Explore SEC and related filing metadata, where available.

AccurEdit Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about AccurEdit Therapeutics's valuation, stock price, and market status.

Is AccurEdit Therapeutics a public or private company?

AccurEdit Therapeutics is a private company.

What is the current stock price of AccurEdit Therapeutics?

AccurEdit Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is AccurEdit Therapeutics worth (valuation)?

Valuation information for AccurEdit Therapeutics is not publicly available.

Can I buy AccurEdit Therapeutics stock?

AccurEdit Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was AccurEdit Therapeutics's last funding round?

Funding round information for AccurEdit Therapeutics is not publicly available.

Who are the main investors in AccurEdit Therapeutics?

Investor information for AccurEdit Therapeutics is not publicly disclosed.

Will AccurEdit Therapeutics IPO soon?

No public IPO plans have been announced for AccurEdit Therapeutics.

How can I track AccurEdit Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AccurEdit Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersJiangsu
Employee Range12
Year Founded2021
Last FundingSep 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?